Camurus, Rhythm Holding deal

Camurus granted Rhythm worldwide rights to develop and commercialize Camurus’ FluidCrystal sustained duration technology in combination with Rhythm’s setmelanotide. Camurus’ FluidCrystal technology delivers therapeutics over extended periods from a single injection.

Setmelanotide is in Phase II testing to treat proopiomelanocortin ( POMC)-null obesity and has breakthrough therapy designation from FDA in the indication. Rhythm has exclusive, worldwide rights to the small peptide melanocortin 4 receptor (MC4R) agonist from Ipsen Group (Euronext:IPN; Pink: IPSEY, Boulogne-Billancourt, France) under a 2010 deal. ...